Protalix BioTherapeutics (PLX) Other Non Operating Income (2010 - 2026)
Protalix BioTherapeutics' quarterly Other Non Operating Income came in at $188000.0 in Q1 2026, down 55.13% year-on-year from $419000.0 in Q1 2025, and down 29.06% quarter-over-quarter from $265000.0 in Q4 2025.
Protalix BioTherapeutics has reported Other Non Operating Income for 17 years, with the latest figure at $188000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 55.13% year-over-year to $188000.0; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (up 145.87% YoY), and the FY2025 full-year result was $1.1 million, up 114.03% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $188000.0, down from $265000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $1.8 million in Q4 2022, with the low at -$680000.0 in Q4 2024.
- Average Other Non Operating Income over 5 years is $365411.8, with a median of $272000.0 recorded in 2025.
- Year-over-year, Other Non Operating Income soared 88500.0% in 2022 and sank 1737.84% in 2024.
- Tracing PLX's Other Non Operating Income over 5 years: stood at $1.8 million in 2022, then sank by 102.09% to -$37000.0 in 2023, then slumped by 1737.84% to -$680000.0 in 2024, then soared by 138.97% to $265000.0 in 2025, then declined by 29.06% to $188000.0 in 2026.
- The last three Other Non Operating Income figures came in at $188000.0 (Q1 2026), $265000.0 (Q4 2025), and $288000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | 265,000.00 |
| Sep 30, 2025 | 288,000.00 |
| Jun 30, 2025 | 272,000.00 |
| Mar 31, 2025 | 419,000.00 |
| Dec 31, 2024 | -680,000.00 |
| Sep 30, 2024 | 151,000.00 |
| Jun 30, 2024 | 522,000.00 |
| Mar 31, 2024 | 513,000.00 |
| Dec 31, 2023 | -37,000.00 |
| Sep 30, 2023 | 628,000.00 |
| Jun 30, 2023 | 531,000.00 |
| Mar 31, 2023 | 172,000.00 |
| Dec 31, 2022 | 1.77 Mn |
| Sep 30, 2022 | 197,000.00 |
| Jun 30, 2022 | 813,000.00 |
| Mar 31, 2022 | 202,000.00 |
| Dec 31, 2021 | -2,000.00 |
| Sep 30, 2021 | 96,000.00 |
| Jun 30, 2021 | 128,000.00 |
| Mar 31, 2021 | 335,000.00 |
| Dec 31, 2020 | 79,000.00 |
| Sep 30, 2020 | 118,000.00 |
| Jun 30, 2020 | 38,000.00 |
| Mar 31, 2020 | 203,000.00 |
| Dec 31, 2019 | 180,000.00 |
| Sep 30, 2019 | 34,000.00 |
| Jun 30, 2019 | 3,000.00 |
| Mar 31, 2019 | 190,000.00 |
| Dec 31, 2018 | 99,000.00 |
| Sep 30, 2018 | 230,000.00 |
| Jun 30, 2018 | 75,000.00 |
| Mar 31, 2018 | 132,000.00 |
| Sep 30, 2017 | 8,000.00 |
| Jun 30, 2017 | 40,000.00 |
| Mar 31, 2017 | 1.63 Mn |
| Dec 31, 2016 | 14.06 Mn |
| Sep 30, 2016 | 268,000.00 |
| Jun 30, 2016 | 96,000.00 |
| Mar 31, 2016 | 242,000.00 |
| Dec 31, 2015 | 59,000.00 |
| Sep 30, 2015 | 17,000.00 |
| Jun 30, 2015 | 43,000.00 |
| Mar 31, 2015 | 28,000.00 |
| Mar 31, 2014 | 687,000.00 |
| Dec 31, 2013 | -1.88 Mn |
| Sep 30, 2013 | 1.08 Mn |
| Jun 30, 2013 | 800,000.00 |
| Mar 31, 2013 | 400,000.00 |
| Dec 31, 2012 | -1.12 Mn |
| Sep 30, 2012 | 1.67 Mn |
| Jun 30, 2012 | -855,000.00 |
| Mar 31, 2012 | 161,000.00 |
| Dec 31, 2011 | -5.48 Mn |
| Sep 30, 2011 | -108,000.00 |
| Jun 30, 2011 | -5.38 Mn |
| Mar 31, 2011 | 1.87 Mn |
| Dec 31, 2010 | 320,000.00 |
| Sep 30, 2010 | 374,000.00 |
| Jun 30, 2010 | 109,000.00 |